Skip to main content
Top
Published in: Tumor Biology 5/2013

01-10-2013 | Research Article

TF/FVIIa/PAR2 promotes cell proliferation and migration via PKCα and ERK-dependent c-Jun/AP-1 pathway in colon cancer cell line SW620

Authors: Lichao Hu, Longfei Xia, Hong Zhou, Biao Wu, Yuan Mu, Ying Wu, Jinchuan Yan

Published in: Tumor Biology | Issue 5/2013

Login to get access

Abstract

Our previous study has demonstrated that tissue factor–factor VIIa (TF/FVIIa) complex promotes the proliferation and migration of colon cancer cell line SW620 through the activation of protease-activated receptor 2 (PAR2). In the current study, the underlying molecular mechanisms of TF/FVIIa/PAR2 signaling in SW620 cells were further explored, with the focus on the role of activator protein-1 (AP-1) subunit c-Jun. The results revealed that PAR2-AP and FVIIa could upregulate c-Jun expression and c-Jun phosphorylation in SW620 cells in a time-dependent manner. The effect of FVIIa was significantly blocked by anti-TF and anti-PAR2 antibodies. Protein kinase Cα (PKCα) inhibitor safingol and extracellular signal-regulated kinase 1 and 2 (ERK1/2) inhibitor U0126 abrogated the activation of c-Jun. In contrast, Ca2+ chelators EGTA and thapsigargin, and p38MAPK inhibitor SB203580 had no effect. Suppression of c-Jun/AP-1 activation using a natural inhibitor curcumin decreased the expression of caspase-3, MMP-9, and TF, as well as the proliferation and migration of SW620 cells induced by PAR2-AP or FVIIa. Collectively, our findings suggest that c-Jun/AP-1 activation is required for TF/FVIIa/PAR2-induced SW620 cell proliferation and migration. PKCα and ERK1/2 are located upstream of c-Jun/AP-1 in this signaling pathway. Pharmacological inhibition of this pathway might be a novel strategy for colon cancer therapy.
Appendix
Available only for authorised users
Literature
2.
go back to reference Schaffner F, Yokota N, Ruf W. Tissue factor proangiogenic signaling in cancer progression. Thromb Res. 2012;129:S127–31.CrossRefPubMed Schaffner F, Yokota N, Ruf W. Tissue factor proangiogenic signaling in cancer progression. Thromb Res. 2012;129:S127–31.CrossRefPubMed
4.
go back to reference Adams MN, Ramachandran R, Yau MK, Suen JY, Fairlie DP, Hollenberg MD, et al. Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther. 2011;130:248–82.CrossRefPubMed Adams MN, Ramachandran R, Yau MK, Suen JY, Fairlie DP, Hollenberg MD, et al. Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther. 2011;130:248–82.CrossRefPubMed
5.
go back to reference Su S, Li Y, Luo Y, Sheng Y, Su Y, Padia RN, et al. Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene. 2009;28:3047–57.PubMedCentralCrossRefPubMed Su S, Li Y, Luo Y, Sheng Y, Su Y, Padia RN, et al. Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene. 2009;28:3047–57.PubMedCentralCrossRefPubMed
6.
go back to reference Kaufmann R, Oettel C, Horn A, Halbhuber KJ, Eitner A, Krieg R, et al. Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2 mediated hepatocellular carcinoma cell invasion. Carcinogenesis. 2009;30:1487–96.CrossRefPubMed Kaufmann R, Oettel C, Horn A, Halbhuber KJ, Eitner A, Krieg R, et al. Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2 mediated hepatocellular carcinoma cell invasion. Carcinogenesis. 2009;30:1487–96.CrossRefPubMed
7.
go back to reference Darmoul D, Gratio V, Devaud H, Laburthe M. Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem. 2004;279:20927–34.CrossRefPubMed Darmoul D, Gratio V, Devaud H, Laburthe M. Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem. 2004;279:20927–34.CrossRefPubMed
8.
go back to reference Wu B, Zhou H, Hu L, Mu Y, Wu Y. Involvement of PKCα activation in TF/VIIa/PAR2-induced proliferation, migration, and survival of colon cancer cell SW620. Tumor Biol. 2013;34:837–46.CrossRef Wu B, Zhou H, Hu L, Mu Y, Wu Y. Involvement of PKCα activation in TF/VIIa/PAR2-induced proliferation, migration, and survival of colon cancer cell SW620. Tumor Biol. 2013;34:837–46.CrossRef
9.
go back to reference Zhou H, Hu H, Shi W, Ling S, Wang T, Wang H. The expression and the functional roles of tissue factor and protease-activated receptor-2 on SW620 cells. Oncol Rep. 2008;20:1069–76.PubMed Zhou H, Hu H, Shi W, Ling S, Wang T, Wang H. The expression and the functional roles of tissue factor and protease-activated receptor-2 on SW620 cells. Oncol Rep. 2008;20:1069–76.PubMed
10.
go back to reference Wu Y, Zhang X, Zhou H, Chen D, Xie H, Mu Y, et al. Factor VIIa regulates the expression of caspase-3, MMP-9, and CD44 in SW620 colon cancer cells involving PAR2/MAPKs/NF-κB signaling pathways. Cancer Invest. 2013;31:7–16.CrossRefPubMed Wu Y, Zhang X, Zhou H, Chen D, Xie H, Mu Y, et al. Factor VIIa regulates the expression of caspase-3, MMP-9, and CD44 in SW620 colon cancer cells involving PAR2/MAPKs/NF-κB signaling pathways. Cancer Invest. 2013;31:7–16.CrossRefPubMed
11.
go back to reference Ozanne BW, Spence HJ, McGarry LC, Hennigan RF. Transcription factors control invasion: AP-1 the first among equals. Oncogene. 2007;26:1–10.CrossRefPubMed Ozanne BW, Spence HJ, McGarry LC, Hennigan RF. Transcription factors control invasion: AP-1 the first among equals. Oncogene. 2007;26:1–10.CrossRefPubMed
12.
go back to reference Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci. 2004;117:5965–73.CrossRefPubMed Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci. 2004;117:5965–73.CrossRefPubMed
13.
go back to reference Price M, Badaut J, Thevenet J, Hirt L. Activation of c-Jun in the nuclei of neurons of the CA-1 in thrombin preconditioning occurs via PAR-1. J Neurosci Res. 2010;88:1338–47.PubMed Price M, Badaut J, Thevenet J, Hirt L. Activation of c-Jun in the nuclei of neurons of the CA-1 in thrombin preconditioning occurs via PAR-1. J Neurosci Res. 2010;88:1338–47.PubMed
14.
go back to reference Kastl SP, Speidl WS, Katsaros KM, Kaun C, Rega G, Assadian A, et al. Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. Blood. 2009;114:2812–8.CrossRefPubMed Kastl SP, Speidl WS, Katsaros KM, Kaun C, Rega G, Assadian A, et al. Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. Blood. 2009;114:2812–8.CrossRefPubMed
15.
go back to reference Jin H, Tan X, Liu X, Ding Y. Downregulation of AP-1 gene expression is an initial event in the oridonin-mediated inhibition of colorectal cancer: studies in vitro and in vivo. J Gastroenterol Hepatol. 2011;26:706–15.CrossRefPubMed Jin H, Tan X, Liu X, Ding Y. Downregulation of AP-1 gene expression is an initial event in the oridonin-mediated inhibition of colorectal cancer: studies in vitro and in vivo. J Gastroenterol Hepatol. 2011;26:706–15.CrossRefPubMed
16.
go back to reference Vaiopoulos AG, Papachroni KK, Papavassiliou AG. Colon carcinogenesis: Learning from NF-kappaB and AP-1. Int J Biochem Cell Biol. 2010;42:1061–5.CrossRefPubMed Vaiopoulos AG, Papachroni KK, Papavassiliou AG. Colon carcinogenesis: Learning from NF-kappaB and AP-1. Int J Biochem Cell Biol. 2010;42:1061–5.CrossRefPubMed
17.
go back to reference Zhou H, Shi W, Zhou B, Guo D, Wang T. Tissue factor-factor VIIa regulates interleukin-8, tissue factor and caspase-7 expression in SW620 cells through protease-activated receptor-2 activation. Mol Med Report. 2010;3:269–74. Zhou H, Shi W, Zhou B, Guo D, Wang T. Tissue factor-factor VIIa regulates interleukin-8, tissue factor and caspase-7 expression in SW620 cells through protease-activated receptor-2 activation. Mol Med Report. 2010;3:269–74.
18.
go back to reference van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood. 2012;119:924–32.CrossRefPubMed van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood. 2012;119:924–32.CrossRefPubMed
19.
go back to reference Rao B, Gao Y, Huang J, Gao X, Fu X, Huang M, et al. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis. Int J Colorectal Dis. 2011;26:593–601.CrossRefPubMed Rao B, Gao Y, Huang J, Gao X, Fu X, Huang M, et al. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis. Int J Colorectal Dis. 2011;26:593–601.CrossRefPubMed
20.
21.
go back to reference Yu Z, Sato S, Trackman PC, Kirsch KH, Sonenshein GE. Blimp1 Activation by AP-1 in Human Lung Cancer Cells Promotes a Migratory Phenotype and Is Inhibited by the Lysyl Oxidase Propeptide. PLoS One. 2012;7:e33287.PubMedCentralCrossRefPubMed Yu Z, Sato S, Trackman PC, Kirsch KH, Sonenshein GE. Blimp1 Activation by AP-1 in Human Lung Cancer Cells Promotes a Migratory Phenotype and Is Inhibited by the Lysyl Oxidase Propeptide. PLoS One. 2012;7:e33287.PubMedCentralCrossRefPubMed
22.
go back to reference Jia ZC, Wan YL, Tang JQ, Dai Y, Liu YC, Wang X, et al. Tissue factor/activated factor VIIa induces matrix metalloproteinase-7 expression through activation of c-Fos via ERK1/2 and p38 MAPK signaling pathways in human colon cancer cell. Int J Colorectal Dis. 2012;27:437–45.CrossRefPubMed Jia ZC, Wan YL, Tang JQ, Dai Y, Liu YC, Wang X, et al. Tissue factor/activated factor VIIa induces matrix metalloproteinase-7 expression through activation of c-Fos via ERK1/2 and p38 MAPK signaling pathways in human colon cancer cell. Int J Colorectal Dis. 2012;27:437–45.CrossRefPubMed
23.
go back to reference Zuo Z, Cai T, Li J, Zhang D, Yu Y, Huang C. Hexavalent Chromium Cr(VI) Up-Regulates COX-2 Expression through an NFkappaB/c-Jun/AP-1-Dependent Pathway. Environ Health Perspect. 2012;120:547–53.PubMedCentralCrossRefPubMed Zuo Z, Cai T, Li J, Zhang D, Yu Y, Huang C. Hexavalent Chromium Cr(VI) Up-Regulates COX-2 Expression through an NFkappaB/c-Jun/AP-1-Dependent Pathway. Environ Health Perspect. 2012;120:547–53.PubMedCentralCrossRefPubMed
25.
go back to reference Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin Thromb Hemost. 2006;32:24–32.CrossRefPubMed Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin Thromb Hemost. 2006;32:24–32.CrossRefPubMed
26.
go back to reference Song MO, Lee CH, Yang HO, Freedman JH. Endosulfan upregulates AP-1 binding and ARE-mediated transcription via ERK1/2 and p38 activation in HepG2 cells. Toxicology. 2012;292:23–32.PubMedCentralCrossRefPubMed Song MO, Lee CH, Yang HO, Freedman JH. Endosulfan upregulates AP-1 binding and ARE-mediated transcription via ERK1/2 and p38 activation in HepG2 cells. Toxicology. 2012;292:23–32.PubMedCentralCrossRefPubMed
27.
go back to reference Müller I, Endo T, Thiel G. Regulation of AP-1 activity in glucose-stimulated insulinoma cells. J Cell Biochem. 2010;110:1481–94.CrossRefPubMed Müller I, Endo T, Thiel G. Regulation of AP-1 activity in glucose-stimulated insulinoma cells. J Cell Biochem. 2010;110:1481–94.CrossRefPubMed
28.
go back to reference Lin CW, Hou WC, Shen SC, Juan SH, Ko CH, Wang LM, et al. Quercetin inhibition of tumor invasion via suppressing PKC delta/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis. 2008;29:1807–15.CrossRefPubMed Lin CW, Hou WC, Shen SC, Juan SH, Ko CH, Wang LM, et al. Quercetin inhibition of tumor invasion via suppressing PKC delta/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis. 2008;29:1807–15.CrossRefPubMed
29.
go back to reference Müller I, Lipp P, Thiel G. Ca2+ signaling and gene transcription in glucose-stimulated insulinoma cells. Cell Calcium. 2012;52:137–51.CrossRefPubMed Müller I, Lipp P, Thiel G. Ca2+ signaling and gene transcription in glucose-stimulated insulinoma cells. Cell Calcium. 2012;52:137–51.CrossRefPubMed
30.
go back to reference Ruocco KM, Goncharova EI, Young MR, Colburn NH, McMahon JB, Henrich CJ. A high-throughput cell-based assay to identify specific inhibitors of transcription factor AP-1. J Biomol Screen. 2007;12:133–9.CrossRefPubMed Ruocco KM, Goncharova EI, Young MR, Colburn NH, McMahon JB, Henrich CJ. A high-throughput cell-based assay to identify specific inhibitors of transcription factor AP-1. J Biomol Screen. 2007;12:133–9.CrossRefPubMed
31.
go back to reference Ledgerwood EC, Morison IM. Targeting the apoptosome for cancer therapy. Clin Cancer Res. 2009;15:420–4.CrossRefPubMed Ledgerwood EC, Morison IM. Targeting the apoptosome for cancer therapy. Clin Cancer Res. 2009;15:420–4.CrossRefPubMed
32.
go back to reference Daniele A, Zito AF, Giannelli G, Divella R, Asselti M, Mazzocca A, et al. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Res. 2010;30:3521–7.PubMed Daniele A, Zito AF, Giannelli G, Divella R, Asselti M, Mazzocca A, et al. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Res. 2010;30:3521–7.PubMed
33.
go back to reference Hector S, Prehn JH. Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: A review. Biochim Biophys Acta. 2009;1795:117–29.PubMed Hector S, Prehn JH. Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: A review. Biochim Biophys Acta. 2009;1795:117–29.PubMed
34.
go back to reference Groblewska M, Mroczko B, Szmitkowski M. The role of selected matrix metalloproteinases and their inhibitors in colorectal cancer development. Postepy Hig Med Dosw (Online). 2010;64:22–30.PubMed Groblewska M, Mroczko B, Szmitkowski M. The role of selected matrix metalloproteinases and their inhibitors in colorectal cancer development. Postepy Hig Med Dosw (Online). 2010;64:22–30.PubMed
35.
go back to reference Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res. 2009;69:2540–9.PubMedCentralCrossRefPubMed Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res. 2009;69:2540–9.PubMedCentralCrossRefPubMed
36.
go back to reference Provençal M, Berger-Thibault N, Labbé D, Veitch R, Boivin D, Rivard GE, et al. Tissue factor mediates the HGF/Met-induced antiapoptotic pathway in DAOY medulloblastoma cells. J Neurooncol. 2010;97:365–72.CrossRefPubMed Provençal M, Berger-Thibault N, Labbé D, Veitch R, Boivin D, Rivard GE, et al. Tissue factor mediates the HGF/Met-induced antiapoptotic pathway in DAOY medulloblastoma cells. J Neurooncol. 2010;97:365–72.CrossRefPubMed
Metadata
Title
TF/FVIIa/PAR2 promotes cell proliferation and migration via PKCα and ERK-dependent c-Jun/AP-1 pathway in colon cancer cell line SW620
Authors
Lichao Hu
Longfei Xia
Hong Zhou
Biao Wu
Yuan Mu
Ying Wu
Jinchuan Yan
Publication date
01-10-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0803-2

Other articles of this Issue 5/2013

Tumor Biology 5/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine